MERCK KGAA
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1668-01-01
- Employees
- 62.9K
- Market Cap
- $84.2B
- Website
- http://www.merckgroup.com/de
Post-Authorization Observational Study to Evaluate Cognition and Fatigue in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Treated With Rebif®
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2013-09-06
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 300
- Registration Number
- NCT01075880
- Locations
- 🇨🇿
Neurologicka klinika FNBB, Brno, Czech Republic
🇨🇿Neurologicka klinika, Fakultní nemocnice U Sv. Anny, Brno, Czech Republic
🇨🇿Neurologicka klinika, Fakultní nemocnice, Olomouc, Czech Republic
A Pilot Trial of Interferon Beta-1a in Alzheimer's Disease
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 42
- Registration Number
- NCT01075763
- Locations
- 🇮🇹
U.VA. Neurologia - Azienda Ospedaliera Garibaldi Nesina, Catania, CT, Italy
A Clinical Trial to Determine the Effect of Lutropin Alfa on Embryo Quality and Implantation Rate in Advanced Reproductive Age
Phase 2
Terminated
- Conditions
- InfertilityOvulation Induction
- Interventions
- Drug: Recombinant human luteinizing hormone (rhLH)Drug: Recombinant follicle-stimulating hormone (rFSH)
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2014-02-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 76
- Registration Number
- NCT01075815
- Locations
- 🇪🇸
FivMadrid, C/ Marqués de Urquijo, 26,, Madrid, Spain
An Observational Study of Gonal-F Filled by Mass Pens in Multifollicular Stimulation Prior to In-vitro Fertilization (IVF) or Intracytoplasmic Sperm Injection (ICSI)
Completed
- Conditions
- Multifollicular Stimulation
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2014-07-31
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 1539
- Registration Number
- NCT01075854
- Locations
- 🇰🇷
Maria Fertility Hospital, Seoul, Korea, Republic of
An Observational Study to Assess the Quality of Life of the Patients With Multiple Sclerosis and Their Caregivers
Completed
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2014-02-17
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 141
- Registration Number
- NCT01075737
- Locations
- 🇦🇷
25 de Mayo 138, Capital, Pcia. de, Santiago del Estero, Argentina
An Observational Study to Examine the Patients With Isolated Systolic Hypertonia (ISH) Under Therapy With Eneas® (NIS ENEAS ISH)
Completed
- Conditions
- Hypertension
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2014-02-19
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 2065
- Registration Number
- NCT01074281
Tolerability of Rebif® (Interferon-beta 1-A) Therapy in Korean Patients With Multiple Sclerosis
Completed
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2014-02-19
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 60
- Registration Number
- NCT01074346
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, 50 Ilwon-dong, Gangnam-gu, Korea, Republic of
An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment
Terminated
- Conditions
- Colorectal Neoplasm
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 146
- Registration Number
- NCT01074333
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea
Phase 4
Completed
- Conditions
- Heart Failure, Congestive
- Interventions
- First Posted Date
- 2010-02-24
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 180
- Registration Number
- NCT01074307
- Locations
- 🇰🇷
Konkuk University Medical Center, Seoul, Korea, Republic of
Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle
Phase 3
Terminated
- Conditions
- Reproductive Techniques, Assisted
- Interventions
- Drug: Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH)Drug: r-hFSH
- First Posted Date
- 2010-02-19
- Last Posted Date
- 2013-12-27
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 133
- Registration Number
- NCT01071200
- Locations
- 🇮🇹
Merck Serono S.p.A., Roma, Italy
© Copyright 2025. All Rights Reserved by MedPath